Efficacy of a novel device for cryoprevention of oral mucositis: a randomized, blinded, multicenter, parallel group, phase 3 trial

AbstractCryoprevention (CP) using ice (IC) is an effective strategy to prevent chemotherapy-induced oral mucositis (OM). However, the use of IC may cause adverse reactions and requires water of safe quality to minimize risk of serious infections. This randomized, blinded, parallel group, phase 3 trial was conducted in five Scandinavian centers. Eligible patients were diagnosed with multiple myeloma or lymphoma, scheduled to receive conditioning with high-dose chemotherapy prior to autologous hematopoietic stem cell transplantation (ASCT). Patients were assigned to cooling with IC or a novel intraoral cooling device (ICD). The primary outcome was the highest OM score during the study period, expressed as peak value on the Oral Mucositis Assessment Scale (OMAS–total). When the entire study population (n = 172) was analyzed for peak OMAS–total, the two cooling methods were equally effective. However, when the lymphoma group was analyzed separately, the ICD significantly reduced the peak OMAS–total score to a greater extent compared to IC (x̄ ± SD; 1.77 ± 1.59 vs. 3.08 ± 1.50; p = 0.047). Combined with existing evidence, the results of the present trial confirm that CP is an effective method to prevent OM. ClinicalTrials.gov. NCT03203733.

Download Full-text

High-dose chemotherapy (HDCT) with hematopoietic stem cell transplantation (HSCT) in high-risk breast cancer (BC) patients with ≥4 involved axillary lymph nodes (ALN): 20-year follow-up of a randomized phase 3 study

Annals of Oncology ◽

10.1093/annonc/mdy270.184 ◽

2018 ◽

Vol 29 ◽

pp. viii59

Author(s):

T.G. Steenbruggen ◽

L.C. Steggink ◽

C.M. Seynaeve ◽

J.J.M. van der Hoeven ◽

M.J. Hooning ◽

...

Keyword(s):

High Dose Chemotherapy ◽

Axillary Lymph Nodes ◽

High Dose ◽

Axillary Lymph ◽

Phase 3 ◽

Hematopoietic Stem ◽

High Risk Breast Cancer ◽

High Risk Breast ◽

Risk Breast Cancer

Download Full-text

High-dose chemotherapy and hematopoietic stem cell transplantation for breast cancer: Past or future?

Seminars in Oncology ◽

10.1053/sonc.2001.26148 ◽

2001 ◽

Vol 28 (4) ◽

pp. 377-388 ◽

Cited By ~ 1

Author(s):

Roy D. Baynes ◽

Roger D. Dansey ◽

Jared L. Klein ◽

Caroline Hamm ◽

Mark Campbell ◽

...

Keyword(s):

Breast Cancer ◽

Stem Cell ◽

Hematopoietic Stem Cell Transplantation ◽

Stem Cell Transplantation ◽

Cell Transplantation ◽

Hematopoietic Stem Cell ◽

High Dose Chemotherapy ◽

High Dose ◽

Hematopoietic Stem

Download Full-text

PROSPECTS FOR HIGH-DOSE CHEMOTHERAPY WITH AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN THE FIRST LINE OF THERAPY FOR AGGRESSIVE NON-HODGKIN’S LYMPHOMAS

Problems in oncology ◽

10.37469/0507-3758-2017-63-2-326-328 ◽

2017 ◽

Vol 63 (2) ◽

pp. 326-328

Author(s):

Larisa Filatova ◽

Yevgeniya Kharchenko ◽

Sergey Alekseev ◽

Ilya Zyuzgin ◽

Anna Artemeva ◽

...

Keyword(s):

Stem Cell ◽

Stem Cell Transplantation ◽

Cell Transplantation ◽

Therapeutic Option ◽

B Cell Lymphoma ◽

High Dose Chemotherapy ◽

High Dose ◽

First Line ◽

Hematopoietic Stem ◽

Hodgkin's Lymphomas

Currently there is no single approach to treatment for aggressive diffuse large-cell B-cell lymphoma (Double-HIT and Triple-HIT). Accumulated world data remain controversial and, given the unfavorable prognosis in this subgroup, high-dose chemotherapy with autologous stem cell transplantation in the first line of treatment is a therapeutic option.

Download Full-text

SS-4 High dose chemotherapy with autologous hematopoietic stem cell transplantation for CNS lymphoma

Neuro-Oncology Advances ◽

10.1093/noajnl/vdaa143.005 ◽

2020 ◽

Vol 2 (Supplement_3) ◽

pp. ii2-ii2

Author(s):

Eisei Kondo

Keyword(s):

Stem Cell ◽

Hematopoietic Stem Cell Transplantation ◽

Stem Cell Transplantation ◽

Cell Transplantation ◽

Hematopoietic Stem Cell ◽

Primary Cns Lymphoma ◽

High Dose Chemotherapy ◽

Cns Lymphoma ◽

High Dose ◽

Hematopoietic Stem

Abstract High-dose chemotherapy followed by autologous hematopoietic stem cell transplantation (HDT-ASCT) is listed as a consolidation therapy option for primary central nervous system (CNS) lymphoma in the guidelines of western countries. The advantages of HDT-ASCT for primary CNS lymphoma as consolidation are believed to be high rates of long-term remission and lower neurotoxicity, even though its eligibility is limited to younger fit patients. In the Japanese guideline, HDT-ASCT for primary CNS lymphoma is however not recommended in daily practice, mainly because thiotepa was unavailable since 2011. The Japanese registry data for hematopoietic transplantation have shown that primary CNS lymphoma patients were treated with various HDT regimens and thiotepa-containing HDT was associated with better progression free survival (P=.019), lower relapse (P=.042) and a trend toward a survival benefit (Kondo E et al, Biol Blood Marrow Transplant 2019). A pharmacokinetic study of thiotepa(DSP-1958) in HDT-ASCT for lymphoma was conducted in 2017, and thiotepa was approved for HDT-ASCT in lymphoma this March, meaning that optimal HDT regimen for CNS lymphoma is now available in Japan. The treatment strategy of CNS lymphoma needs further development to improve survival and reduce toxicity.

Download Full-text

Impact of Mantle Cell Lymphoma Contamination of Autologous Stem Cell Grafts on Outcome After High-Dose Chemotherapy

Cancers ◽

10.3390/cancers13112558 ◽

2021 ◽

Vol 13 (11) ◽

pp. 2558

Author(s):

Malte Roerden ◽

Stefan Wirths ◽

Martin Sökler ◽

Wolfgang A. Bethge ◽

Wichard Vogel ◽

...

Keyword(s):

Stem Cell ◽

Mantle Cell Lymphoma ◽

Clinical Decision Making ◽

Cell Lymphoma ◽

High Dose Chemotherapy ◽

High Dose ◽

Hematopoietic Stem ◽

Increased Risk ◽

Mantle Cell ◽

Autologous Grafts

Novel predictive factors are needed to identify mantle cell lymphoma (MCL) patients at increased risk for relapse after high-dose chemotherapy and autologous hematopoietic stem cell transplantation (HDCT/Auto-HSCT). Although bone marrow and peripheral blood involvement is commonly observed in MCL and lymphoma cell contamination of autologous stem cell grafts might facilitate relapse after Auto-HSCT, prevalence and prognostic significance of residual MCL cells in autologous grafts are unknown. We therefore performed a multiparameter flow cytometry (MFC)-based measurable residual disease (MRD) assessment in autologous stem cell grafts and analyzed its association with clinical outcome in an unselected retrospective cohort of 36 MCL patients. MRD was detectable in four (11%) autologous grafts, with MRD levels ranging from 0.002% to 0.2%. Positive graft-MRD was associated with a significantly shorter progression-free and overall survival when compared to graft-MRD negative patients (median 9 vs. 56 months and 25 vs. 132 months, respectively) and predicted early relapse after Auto-HSCT (median time to relapse 9 vs. 44 months). As a predictor of outcome after HDCT/Auto-HSCT, MFC-based assessment of graft-MRD might improve risk stratification and support clinical decision making for risk-oriented treatment strategies in MCL.

Download Full-text

High-Dose Chemotherapy with Autologous Hematopoietic Stem-Cell Rescue for Pediatric Brain Tumor Patients: A Single Institution Experience from UCLA

Journal of Transplantation ◽

10.1155/2011/740673 ◽

2011 ◽

Vol 2011 ◽

pp. 1-11 ◽

Cited By ~ 3

Author(s):

Eduard H. Panosyan ◽

Alan K. Ikeda ◽

Vivian Y. Chang ◽

Dan R. Laks ◽

Charles L. Reeb ◽

...

Keyword(s):

Stem Cell ◽

Brain Tumors ◽

Hematopoietic Stem Cell ◽

Germ Cell Tumors ◽

Pediatric Brain Tumors ◽

High Dose Chemotherapy ◽

High Dose ◽

Hematopoietic Stem ◽

Stem Cell Rescue ◽

Pediatric Brain

Background. Dose-dependent response makes certain pediatric brain tumors appropriate targets for high-dose chemotherapy with autologous hematopoietic stem-cell rescue (HDCT-AHSCR).Methods. The clinical outcomes and toxicities were analyzed retrospectively for 18 consecutive patients ≤19 y/o treated with HDCT-AHSCR at UCLA (1999–2009).Results. Patients' median age was 2.3 years. Fourteen had primary and 4 recurrent tumors: 12 neural/embryonal (7 medulloblastomas, 4 primitive neuroectodermal tumors, and a pineoblastoma), 3 glial/mixed, and 3 germ cell tumors. Eight patients had initial gross-total and seven subtotal resections. HDCT mostly consisted of carboplatin and/or thiotepa ± etoposide (n=16). Nine patients underwent a single AHSCR and nine ≥3 tandems. Three-year progression-free and overall survival probabilities were 60.5% ± 16 and 69.3% ± 11.5. Ten patients with pre-AHSCR complete remissions were alive/disease-free, whereas 5 of 8 with measurable disease were deceased (median followup: 2.3 yrs). Nine of 13 survivors avoided radiation. Single AHSCR regimens had greater toxicity than ≥3 AHSCR (P<.01).Conclusion. HDCT-AHSCR has a definitive, though limited role for selected pediatric brain tumors with poor prognosis and pretransplant complete/partial remissions.

Download Full-text